JC Capital
VC Fund
Beijing, China
JC Capital is a venture capital institution specialized in early and mid-term technology investment.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries JC Capital invests in
Stages JC Capital invests in
Countries JC Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $704k–$5.9M
- Series A
- $1.5M–$15M
- Series B
- $2.9M–$14M
Investment Focus
Industry
- Health Care 9 (22%)
- Medical 6 (15%)
- Biotechnology 6 (15%)
- Internet 5 (12%)
- Software 5 (12%)
Stage
- Series A 22 (54%)
- Series B 6 (15%)
- Seed 5 (12%)
- Angel 5 (12%)
- Series C 1 (2%)
Country
- China 36 (88%)
- Vietnam 1 (2%)
- Philippines 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sun Zhixing
Executive Director
|
Executive Director | Total investments: 1 | Find email | |
Xianyue Guǎn
Founding Partner
|
Founding Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Guangna Siwei is an optoelectronic device seller. | $29.6M / Venture - Series Unknown / Aug 05, 2026 | ||
Giant Microbiology
|
Giant Microbiology is a company that produces synthetic biological raw materials in an environmentally friendly manner for the fields of beauty and daily chemicals, functional foods, and medical beauty.. The business focuses on creating "high-gross-profit innovative products" that satisfy consumer demand and offer useful, cutting-edge rawmaterial solutions, with bioactive sugars serving as its starting point. Hyaluronic acid, oligosaccharides, and functional oligosaccharides are among the goods it primarily develops and produces. | Series A / Nov 26, 2025 | |
|
Guangna Anliao
|
Guangna Anliao is a forward-looking technology company dedicated to the research, development, and innovation of advanced medical devices. The company focuses on creating high-quality, reliable solutions that support modern healthcare needs, with an emphasis on improving patient outcomes, enhancing clinical efficiency, and driving technologicalprogress in the medical field. | Series A / Sep 30, 2025 | |
| Xunsheng Medical is a biotechnology business that focuses on the research and development of tumor immunotherapy medications. | Series A / Aug 18, 2025 | ||
| Zhizhen Precision is a high-end integrated circuit test equipment developer. | Series A / Nov 17, 2023 | ||
| Sietium is a high-tech company that independently designs and develops GPU chips and GPU solutions. | $14.5M / Series A / Apr 18, 2023 | ||
| Dragonfly Automation Software provides management and control system product solutions for customers in aerospace, machinery manufacturing, factory automation, and high-end precision instruments. | $12.9M / Series A / Dec 16, 2022 | ||
| Jingda Bio is a biological cell drug developer dedicated to the research and development of general-purpose NK/CAR-NK cell drugs. | Seed / Jun 21, 2022 | ||
| Phenomenon Array is a computer system developer, dedicated to FPGA-based replacement of CPU for storage and computing. | Series A / May 12, 2022 | ||
| Fino Gate is a project-construction company. Non-von Neumann general-purpose network computing system that is autonomous and controllable. concentrates on developing a new generation of controllable computer systems. Empower the computing power infrastructure represented by data centers and intelligent computing centers, as well as 5G, artificialintelligence, cloud computing, blockchain, and industrial IoT, through edge computing equipment, edge cloud, an AI middle platform, and four-tier products for vertical industry applications. The development of the Internet's new technological infrastructure can be used in the areas of intelligent security, transportation, and water conservation. | Series A / May 12, 2022 | ||
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does JC Capital invest in?
JC Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 41 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is JC Capital's check size?
JC Capital typically joins rounds of $704k–$5.9M at Seed, $1.5M–$15M at Series A and $2.9M–$14M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds JC Capital participates in.
How do I contact JC Capital?
Public channels for JC Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at JC Capital?
The team at JC Capital includes Sun Zhixing (Executive Director) and Xianyue Guǎn (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
